# Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

> **NCT02532712** · PHASE1 · COMPLETED · sponsor: **Enzychem Lifesciences Corporation** · enrollment: 64 (actual)

## Conditions studied

- Chemotherapy-Induced Neutropenia

## Interventions

- **DRUG:** EC-18
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02532712
- **Lead sponsor:** Enzychem Lifesciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532712, "Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02532712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*